

**WOCKHARDT LIMITED**

Wockhardt Towers, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051, India



**AUDITED CONSOLIDATED FINANCIAL RESULTS**

**FOR THE YEAR ENDED 31ST MARCH, 2014**

(Rs. In Crore)

PARTICULARS	QUARTER ENDED 31/03/2014	% TO SALES	QUARTER ENDED 31/12/2013	% TO SALES	GROWTH %	QUARTER ENDED 31/03/2013	% TO SALES	GROWTH %	YEAR ENDED 31/03/2014	% TO SALES	YEAR ENDED 31/03/2013	% TO SALES	GROWTH %
	Unaudited		Unaudited			Unaudited			Audited		Audited		
Income from Operations	1,038	100.0	1,237	100.0	(16.1)	1,486	100.0	(30.1)	4,830	100.0	5,610	100.0	(13.9)
Total Expenditure	916	88.2	996	80.5	(8.0)	940	63.3	(2.6)	3,850	79.7	3,519	62.7	9.4
a) (Increase)/Decrease in stock	(74)	(7.1)	109	8.8	(167.9)	(12)	(0.8)	516.7	73	1.5	(180)	(3.2)	(140.6)
b) Consumption of raw material	209	20.1	201	16.2	4.0	278	18.7	(24.8)	948	19.6	1,253	22.3	(24.3)
c) Purchase of Finished Goods	251	24.2	149	12.0	68.5	130	8.7	93.1	775	16.0	637	11.4	21.7
Material Consumption	386	37.2	459	37.1	(15.9)	396	26.6	(2.5)	1,796	37.2	1,710	30.5	5.0
d) Staff Cost	167	16.1	176	14.2	(5.1)	140	9.4	19.3	664	13.7	585	10.4	13.5
e) R & D expenditure	101	9.7	98	7.9	3.1	130	8.7	(22.3)	403	8.3	313	5.6	28.8
f) Other expenditure	262	25.2	263	21.3	(0.4)	274	18.4	(4.4)	987	20.4	911	16.2	8.3
Other Expenditure	530	51.1	537	43.4	(1.3)	544	36.6	(2.6)	2,054	42.5	1,809	32.2	13.5
Gross Profit before Interest, Depreciation & Taxation	122	11.8	241	19.5	(49.4)	546	36.7	(77.7)	980	20.3	2,091	37.3	(53.1)
Interest/ Financing Cost													
(a) Interest	16	1.5	31	2.5	(48.4)	60	4.0	(73.3)	83	1.7	215	3.8	(61.4)
(b) (Income)/Expense due to Exchange Rate Fluctuation	(12)		(80)			26			(46)		28		
Depreciation	34	3.3	34	2.7	-	33	2.2	3.0	140	2.9	122	2.2	14.8
Other Income	8	-	7	-	-	11	-	-	38	-	51	-	-
Profit/(Loss) Before Tax before exceptional items	92	8.9	263	21.3	(65.0)	438	29.5	(79.0)	841	17.4	1,777	31.7	(52.7)
Exceptional Item Profit/(Loss)	(9)		54			(10)			50		62		
Profit/(Loss) before Tax	83	8.0	317	25.6	(73.8)	428	28.8	(80.6)	891	18.4	1,839	32.8	(51.5)
Provision for Taxation Expense/(Credit)	(5)		(17)			103			2		372		
Deferred Taxation (Asset)/ Liability	12		29			(10)			46		(113)		
Profit/(Loss) After Tax	76	7.3	305	24.7	(75.1)	335	22.5	(77.3)	843	17.5	1,580	28.2	(46.6)
Add: Share of Profit/(Loss) from Associates	0		0			0			0		(1)		
Net Profit/(Loss) from continuing operations	76	7.3	305	24.7	(75.1)	335	22.5	(77.3)	843	17.5	1,579	28.1	(46.6)
Profit from Discontinuing operations before tax	-		-			-			-		22		
Tax on Discontinuing operations	-		-			-			-		7		
Profit from Discontinuing operations after tax	-		-			-			-		15		
Net Profit/(Loss) for the period	76	7.3	305	24.7	(75.1)	335	22.5	(77.3)	843	17.5	1,594	28.4	(47.1)
Minority Interest - Profit / (Loss)	1		1			-			2		-		
Net Profit/(Loss) for the period after Minority Interest	75	7.2	304	24.6	(75.3)	335	22.5	(77.6)	841	17.4	1,594	28.4	(47.2)
Paid-up Equity Share Capital (Rs 5/-each)	55		55		-	55			55		55		
Reserves excluding Revaluation Reserve (as per last audited Balance-Sheet)	-		-		-	-			3,210		2,333		
Earnings Per Share													
Basic Earnings Per Share (Rs)	6.83		27.74			30.61			76.67		145.61		
Diluted Earnings Per Share (Rs)	6.75		27.40			30.14			75.74		143.34		



: 2 :

**Notes To Consolidated Financials:-**

- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 26, 2014.
- 2) Subject to the approval of shareholders at the annual general meeting, board has recommended dividend of 0.01% (at the rate of Rs. 0.0005 per share of Rs. 5/- each) on 47,56,59,941 Non-convertible Cumulative Redeemable Preference shares of Rs. 5/- each and 12,14,54,927 Optionally Convertible Cumulative Redeemable Preference Shares of Rs. 5/- each aggregating to Rs. 2,98,557/-. During the year Board of Directors of the Company have declared two interim dividends of 100% each totalling to 200% on equity shares of Rs. 5/- each, absorbing Rs. 109.75 crore. The Board recommends the said interim dividends of 200% as final dividend for the financial year 2013-14.
- 3) During the year, the Company has received regulatory alerts from USFDA on two of its manufacturing units located in Aurangabad. The said action did not affect the sale of inventories which were already lying in USA, thereby assuring no quality concerns on the products. Further, USFDA has also excluded 6 products and the supply of the same continues to the US market. The Company has also received restricted GMP certificate from the UKMHRA for its manufacturing facilities at Aurangabad & Daman. The UKMHRA has however, allowed the Company to manufacture and supply 21 products. The UKMHRA had also initiated drug recalls for the products manufactured at two Aurangabad facilities, but has categorically mentioned that the recalls were only precautionary and there was no risk to patient safety.  
During the year, the Company has reviewed its technical operations and as a result of the same has directed its energies into strengthening and upgrading its Quality & Manufacturing operations. The Company has initiated a number of improvement measures to ensure creation of a robust, sustainable and compliant operating framework on a consistent basis. Some of these measures include restructuring and strengthening Quality & Manufacturing functions, initiating extensive training programs for upgrading competencies and improving information system security and integrity.
- 4) Exceptional items for the year comprises of gain on arbitration in France of Rs. 170 crore, write off of inventory and recall costs Rs. 110 Cr and other exceptional expense Rs. 10 cr
- 5) During the year, the Company has issued and allotted 1,67,750 equity shares of face value of Rs. 5 each pursuant to exercise of employee stock options.
- 6) During the previous year, the Company had divested its Nutrition business. The turnover, total expenditure and profit before tax on discontinuing operations of Nutrition business were as under:

Rs in crore

Particulars	QUARTER ENDED 31/03/2014	QUARTER ENDED 31/12/2013	QUARTER ENDED 31/03/2013	YEAR ENDED 31/3/2014	YEAR ENDED 31/3/2013 *
Turnover	-	-	-	-	111
Total Expenditure	-	-	-	-	89
Profit before tax	-	-	-	-	22

\* Turnover, Total Expenditure and profit before tax upto July 25, 2012.

- 7) Key Financials on Standalone basis:

Rs in Crore

Particulars	QUARTER ENDED 31/03/2014	QUARTER ENDED 31/12/2013	QUARTER ENDED 31/03/2013	YEAR ENDED 31/3/2014	YEAR ENDED 31/3/2013
Net Sales/Income from operations (including discontinuing operations)	420	423	789	1,805	2,582
Profit/ (Loss) Before Tax	33	20	190	214	714
Profit/ (Loss) After Tax	23	26	153	198	623

- 8) The Company is exclusively into Pharmaceutical business Segment.
- 9) Previous period figures have been recast/ re-classified to conform to the current period's presentation.
- 10) Figures for the quarter ended March 31, 2014 and March 31, 2013 are the balancing figures between the audited figures in respect of the full financial year and the published figures up to the third quarter of the relevant financial year.

**WOCKHARDT LIMITED**  
**AUDITED STATEMENT OF CONSOLIDATED ASSETS & LIABILITIES**

Rs. in Crore

Consolidated Statement of Assets and Liabilities	As at 31/03/2014	As at 31/03/2013
Particulars		
<b>AUDITED CONSOLIDATED FINANCIAL RESULTS</b>		
<b>1 Shareholders' funds</b>		
(a) Share capital	353	353
(b) Reserves and surplus	3,228	2,351
(c) Minority Interest	137	0
<b>Sub-total - Shareholders' funds</b>	<b>3,718</b>	<b>2,704</b>
<b>2. Share application money pending allotment</b>		
	0	0
<b>3. Non-current liabilities</b>		
(a) Long-term borrowings	1,102	1,475
(b) Deferred tax liabilities (net)	7	0
(c) Other long-term liabilities	0	0
(c) Long-term provisions	52	70
<b>Sub-total - Non-current liabilities</b>	<b>1,161</b>	<b>1,545</b>
<b>4. Current liabilities</b>		
(a) Short-term borrowings	210	182
(b) Trade payables	558	634
(c) Other current liabilities	948	790
(d) Short-term provisions	27	167
<b>Sub-total - Current liabilities</b>	<b>1,743</b>	<b>1,773</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>6,622</b>	<b>6,022</b>
<b>B ASSETS</b>		
<b>1. Non-current assets</b>		
(a) Fixed assets	2,152	1,754
(b) Goodwill on consolidation	850	726
(c) Non-current investments	3	3
(d) Deferred tax assets (net)	0	24
(e) Long-term loans and advances	236	183
(f) Other non-current assets	25	5
<b>Sub-total - Non-current assets</b>	<b>3,266</b>	<b>2,695</b>
<b>2. Current assets</b>		
(a) Current investments	574	0
(b) Inventories	993	1,059
(c) Trade receivables	481	958
(d) Cash and bank balances	1,126	1,096
(e) Short-term loans and advances	182	214
<b>Sub-total - Current assets</b>	<b>3,356</b>	<b>3,327</b>
<b>Total - ASSETS</b>	<b>6,622</b>	<b>6,022</b>